Suchen
Neumora Therapeutics Inc
NMRAZur Watchlist hinzufügen
1.670USD
+0.050+3.09%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
304.20MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Neumora Therapeutics Inc Unternehmen
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
Neumora Therapeutics Inc Informationen
BörsenkürzelNMRA
Name des UnternehmensNeumora Therapeutics Inc
IPO-datumSep 15, 2023
CEOBerns (Paul L)
Anzahl der mitarbeiter110
WertpapierartOrdinary Share
GeschäftsjahresendeSep 15
Addresse260 Arsenal Place, Suite 1
StadtWATERTOWN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02472
Telefon18577600900
Websitehttps://neumoratx.com/
BörsenkürzelNMRA
IPO-datumSep 15, 2023
CEOBerns (Paul L)
Führungskräfte von Neumora Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.71M
+0.56%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
--
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
34.02K
-265.51%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
21.03K
-6.83%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
20.10K
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Mr. Alaa A. Halawa
Mr. Alaa A. Halawa
Independent Director
Independent Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. David Piacquad
Mr. David Piacquad
Independent Director
Independent Director
--
--
Ms. Helen Rubinstein
Ms. Helen Rubinstein
IR Contact Officer
IR Contact Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.71M
+0.56%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
--
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
34.02K
-265.51%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
21.03K
-6.83%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
20.10K
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Neumora Therapeutics Inc?
Die fünf größten Anteilseigner von Neumora Therapeutics Inc sind: Mr. Paul L. Berns
Wie viele Institutionen halten Anteile an Neumora Therapeutics Inc (NMRA)?
Mit Stand vom 2026Q1 halten 301 Institutionen Anteile an Neumora Therapeutics Inc, mit einem Gesamtmarktwert von etwa 106.55M, was 57.52% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -16535931.00 gestiegen.